Role of the sarcolemmal adenosine triphosphate-sensitive potassium channel in hyperkalemic cardioplegia-induced myocyte swelling and reduced contractility

Ann Thorac Surg. 2006 Jan;81(1):148-53. doi: 10.1016/j.athoracsur.2005.06.055.

Abstract

Background: Hyperkalemic cardioplegia (Plegisol) has been shown to result in myocyte swelling and reduced contractility. We have demonstrated the elimination of these detrimental effects by the addition of an adenosine triphosphate-sensitive K+ (KATP) channel opener. To examine whether the mitochondrial or sarcolemmal KATP channel might be involved, volume and contractility in isolated myocytes from wild-type mice and mice lacking the sarcolemmal KATP channel (Kir6.2-/-) were evaluated.

Methods: Myocytes were perfused for 20 minutes each with control 37 degrees C Tyrode's solution, test solution, and then control solution. Test solutions were (n = 10 per group) either 9 degrees C Plegisol or 9 degrees C Plegisol with 100 micromol/L of diazoxide, a putative mitochondrial-specific KATP channel opener. Cell volume and contractility were measured by digital video microscopy at baseline and during the test solution and reexposure periods.

Results: Myocytes from wild-type mice, perfused with 9 degrees C Plegisol, demonstrated significant cell swelling (11.2% +/- 0.4%; p < 0.01) and diminished contractility (32.5% +/- 9.6% reduction in percent shortening, 47.2% +/- 10.1% reduction in peak velocity of shortening, and 52.0% +/- 8.8% reduction in peak velocity of relengthening; p < 0.05) versus baseline. Cell swelling and diminished contractility were significantly reduced by the addition of diazoxide. In Kir6.2-/- myocytes, Plegisol caused a greatly reduced level of cell swelling (3.2% +/- 0.1%; p < 0.01), and this was unaffected by diazoxide. Contractility was unchanged in Kir6.2-/- myocytes after Plegisol.

Conclusions: The sarcolemmal KATP channel appears necessary for exaggerated cell swelling and reduced contractility to occur after hyperkalemic cardioplegia in mouse myocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bicarbonates / pharmacology
  • Bicarbonates / toxicity
  • Calcium Chloride / pharmacology
  • Calcium Chloride / toxicity
  • Cardioplegic Solutions / chemistry
  • Cardioplegic Solutions / pharmacology
  • Cardioplegic Solutions / toxicity*
  • Cell Size / drug effects
  • Diazoxide / pharmacology*
  • Female
  • Heart Ventricles / cytology
  • In Vitro Techniques
  • Isotonic Solutions / pharmacology
  • Magnesium / pharmacology
  • Magnesium / toxicity
  • Male
  • Mice
  • Mice, Knockout
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / ultrastructure
  • Osmotic Pressure
  • Potassium / pharmacology
  • Potassium / toxicity*
  • Potassium Channels, Inwardly Rectifying / deficiency
  • Potassium Channels, Inwardly Rectifying / genetics
  • Potassium Channels, Inwardly Rectifying / physiology*
  • Potassium Chloride / pharmacology
  • Potassium Chloride / toxicity
  • Sarcolemma / enzymology*
  • Sodium Chloride / pharmacology
  • Sodium Chloride / toxicity

Substances

  • Bicarbonates
  • Cardioplegic Solutions
  • Isotonic Solutions
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • St. Thomas' Hospital cardioplegic solution
  • Tyrode's solution
  • Sodium Chloride
  • Potassium Chloride
  • Magnesium
  • Calcium Chloride
  • Diazoxide
  • Potassium